2.28
0.00
(0.00%)
Real-time:
9:40am BST
LON real-time data - Disclaimer
Currency in GBX unless noted
| Range | 2.25 - 2.28 |
| 52 week | 2.01 - 6.00 |
| Open | 2.28 |
| Vol / Avg. | 78,287.00/489,816.00 |
| Mkt cap | 7.65M* |
| P/E | - |
| Div/yield | - |
| EPS | -0.01* |
| Shares | 336.18M |
| Beta | - |
| Inst. own | - |
| *GBP |
Events
May 31, 2013
Verona Pharma Plc Annual General Meeting
|
|
Key stats and ratios
| Q4 (Dec '12) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -83.63% | -71.82% |
| Return on average equity | -87.40% | -75.65% |
| Employees | 12 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 21 - Alpha House 100 Borough High Street
LONDON, ENG SE1 1LB
United Kingdom - Map
+44-20-78633300 (Phone)
+44-20-78633314 (Fax)
LONDON, ENG SE1 1LB
United Kingdom - Map
+44-20-78633300 (Phone)
+44-20-78633314 (Fax)
Website links
External links
Analyst Estimates - BusinessWeek
Options - MarketWatch
Research Reports - Reuters
Director Dealings - Yahoo Finance
Discussion Group - Google Finance
Advertisement
Description
Verona Pharma plc is a biotechnology company. The Company is engaged in research, discovery and development of drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma, allergic rhinitis (hay fever), and cough. The Company�s operating segments include clinical and basic research. The Company operates in two geographical segments: the United Kingdom and Canada. The Company�s product pipeline focuses on research, discovery and development of new therapeutic drugs for the treatment of chronic respiratory diseases. As on December 31, 2011, the Company had three products, RPL554, novel anti-inflammatory polysaccharides (NAIP) and VRP700. In February 2011, it completed the clinical trial at Centre for Human Drug Research at Leiden University of higher doses of RPL554 in patients with mild asthma.
Officers and directors
| Sven Jan-Anders Karlsson | Chief Executive Officer | |
| Claire Poll | Executive Director | |
| John M. Bottomley | Company Secretary | |
| Clive P. Page Ph.D. | Non-Executive Chairman of the Board | |
| Stuart Bottomley | Non-Executive Director | |
| Patrick Paul Anthony Humphrey Ph.D., OBE | Non-Executive Director | |
| Trevor M. Jones Ph.D., CBE | Non-Executive Director |